Jennette JC. Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol. 2013;17(5):603–6. https://doi.org/10.1007/s10157-013-0869-6.

Article  PubMed  PubMed Central  Google Scholar 

Geetha D, Jefferson JA. ANCA-Associated vasculitis: core curriculum 2020. Am J Kidney Dis. 2020;75(1):124–37. https://doi.org/10.1053/j.ajkd.2019.04.031.

Article  CAS  PubMed  Google Scholar 

Anguiano L, Kain R, Anders HJ. The glomerular crescent: triggers, evolution, resolution, and implications for therapy. Curr Opin Nephrol Hypertens. 2020;29(3):302–9. https://doi.org/10.1097/MNH.0000000000000596.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bajema IM, Wilhelmus S, Alpers CE, et al. Revision of the international society of nephrology/renal pathology society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018;93(4):789–96. https://doi.org/10.1016/j.kint.2017.11.023.

Article  PubMed  Google Scholar 

Kronbichler A, Shin JI, Lee KH, et al. Clinical associations of renal involvement in ANCA-associated vasculitis. Autoimmun Rev. 2020;19(4):102495. https://doi.org/10.1016/j.autrev.2020.102495.

Article  CAS  PubMed  Google Scholar 

Alamo BS, Moi L, Bajema I, et al. Long-term outcome of kidney function in patients with ANCA-associated vasculitis. Nephrol Dial Transplant. Published online January 24, 2024. https://doi.org/10.1093/ndt/gfae018.

Tan JA, Dehghan N, Chen W, Xie H, Esdaile JM, Avina-Zubieta JA. Mortality in ANCA-associated vasculitis: ameta-analysis of observational studies. Ann Rheum Dis. 2017;76(9):1566–74. https://doi.org/10.1136/annrheumdis-2016-210942.

Article  PubMed  Google Scholar 

Rhee RL, Hogan SL, Poulton CJ, et al. Trends in long-term outcomes among patients with antineutrophil cytoplasmic antibody-associated vasculitis with renal disease. Arthritis Rheumatol. 2016;68(7):1711–20. https://doi.org/10.1002/art.39614.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pope V, Sivashanmugathas V, Moodley D, Gunaratnam L, Barra L. Outcomes in ANCA-associated vasculitis patients with end-stage kidney disease on renal replacement therapy-a meta-analysis. Semin Arthritis Rheum. 2023;60:152189. https://doi.org/10.1016/j.semarthrit.2023.152189.

Article  CAS  PubMed  Google Scholar 

Li W, Huang H, Cai M, Yuan T, Sheng Y. Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Update: Genetic Pathogenesis. Front Immunol. 2021;12:624848. Published 2021 Mar 26. https://doi.org/10.3389/fimmu.2021.624848.

Merkel PA, Xie G, Monach PA, et al. Identification of functional and expression polymorphisms associated with risk for antineutrophil cytoplasmic autoantibody-associated vasculitis. Arthritis Rheumatol. 2017;69(5):1054–66. https://doi.org/10.1002/art.40034.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Giorgiutti S, Dieudonne Y, Hinschberger O, et al. Prevalence of antineutrophil cytoplasmic antibody-associated vasculitis and spatial association with quarries in a Region of Northeastern France: a capture-recapture and geospatial analysis. Arthritis Rheumatol. 2021;73(11):2078–85. https://doi.org/10.1002/art.41767.

Article  CAS  PubMed  Google Scholar 

Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663):1532–5. https://doi.org/10.1126/science.1092385.

Article  CAS  PubMed  Google Scholar 

Söderberg D, Segelmark M. Neutrophil extracellular traps in ANCA-associated vasculitis. Front Immunol. 2016;7:256. Published 2016 Jun 30. https://doi.org/10.3389/fimmu.2016.00256.

Tsukui D, Kimura Y, Kono H. Pathogenesis and pathology of anti-neutrophil cytoplasmic antibody(ANCA) -associated vasculitis. J Transl Autoimmun. 2021;4:100094. Published 2021 Mar 3. https://doi.org/10.1016/j.jtauto.2021.100094.

Dick J, Gan PY, Ford SL, et al. C5a receptor 1 promotes autoimmunity, neutrophil dysfunction and injury in experimental anti-myeloperoxidase glomerulonephritis. Kidney Int. 2018;93(3):615–25. https://doi.org/10.1016/j.kint.2017.09.018.

Article  CAS  PubMed  Google Scholar 

Gou SJ, Yuan J, Chen M, Yu F, Zhao MH. Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int. 2013;83(1):129–37. https://doi.org/10.1038/ki.2012.313.

Article  CAS  PubMed  Google Scholar 

•• Jayne DRW, Merkel PA, Schall TJ, Bekker P; ADVOCATE Study Group. Avacopan for the Treatment of ANCA-Associated Vasculitis [published correction appears in N Engl J Med. 2024 Jan 25;390(4):388]. N Engl J Med. 2021;384(7):599–609. https://doi.org/10.1056/NEJMoa2023386. This is a phase 3 clinical trial which showed efficacy of avacopan for remission induction leading to FDA approval.

Shi L. Anti-neutrophil cytoplasmic antibody-associated vasculitis: prevalence, treatment, and outcomes. Rheumatol Int. 2017;37(11):1779–88. https://doi.org/10.1007/s00296-017-3818-y.

Article  CAS  PubMed  Google Scholar 

Gopaluni S, Flossmann O, Little MA, et al. Effect of disease activity at three and six months after diagnosis on long-term outcomes in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2019;71(5):784–91. https://doi.org/10.1002/art.40776.

Article  CAS  PubMed  Google Scholar 

Menez S, Hruskova Z, Scott J, et al. Predictors of renal outcomes in sclerotic class anti-neutrophil cytoplasmic antibody glomerulonephritis. Am J Nephrol. 2018;48(6):465–71. https://doi.org/10.1159/000494840.

Article  CAS  PubMed  Google Scholar 

Novick TK, Chen M, Scott J, et al. Patient outcomes in renal-limited antineutrophil cytoplasmic antibody vasculitis with inactive histology. Kidney Int Rep. 2018;3(3):671–676. Published 2018 Feb 21. https://doi.org/10.1016/j.ekir.2018.01.012.

de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R, et al. Chances of renal recovery for dialysis-dependent ANCA-associated glomerulonephritis [published correction appears in J Am Soc Nephrol. 2007 Dec;18(12):3206. Pusey, Charles D [added]]. J Am Soc Nephrol. 2007;18(7):2189–2197. https://doi.org/10.1681/ASN.2007010066.

Lee T, Gasim A, Derebail VK, et al. Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure. Clin J Am Soc Nephrol. 2014;9(5):905–13. https://doi.org/10.2215/CJN.08290813.

Article  PubMed  PubMed Central  Google Scholar 

•• Kidney Disease: Improving Global Outcomes (KDIGO) ANCA Vasculitis Work Group. KDIGO 2024 Clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Kidney Int. 2024;105(3S):S71-S116. https://doi.org/10.1016/j.kint.2023.10.008. This paper provides guidelines for remission induction and maintenance therapy for AAV based on evidence to date.

Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024;83(1):30–47. Published 2024 Jan 2. https://doi.org/10.1136/ard-2022-223764.

Brix SR, Noriega M, Tennstedt P, et al. Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int. 2018;94(6):1177–88. https://doi.org/10.1016/j.kint.2018.07.020.

Article  CAS  PubMed  Google Scholar 

Bate S, McGovern D, Costigliolo F, et al. The improved kidney risk score in ANCA-associated vasculitis for clinical practice and trials. J Am Soc Nephrol. 2024;35(3):335–46. https://doi.org/10.1681/ASN.0000000000000274.

Article  PubMed  Google Scholar 

Berden AE, Ferrario F, Hagen EC, et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2010;21(10):1628–36. https://doi.org/10.1681/ASN.2010050477.

Article  PubMed  Google Scholar 

Casal Moura M, Fervenza FC, Specks U, Sethi S. Kidney biopsy chronicity grading in antineutrophil cytoplasmic antibody-associated vasculitis. Nephrol Dial Transplant. 2022;37(9):1710–21. https://doi.org/10.1093/ndt/gfab250.

Article  CAS  PubMed  Google Scholar 

de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150(10):670–80. https://doi.org/10.7326/0003-4819-150-10-200905190-00004.

Article  PubMed  Google Scholar 

Harper L, Morgan MD, Walsh M, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis. 2012;71(6):955–60. https://doi.org/10.1136/annrheumdis-2011-200477.

Article  CAS  PubMed  Google Scholar 

Ogino MH, Tadi P. Cyclophosphamide. In: StatPearls. Treasure Island (FL): StatPearls Publishing; July 3, 2023.

Chanouzas D, McGregor JAG, Nightingale P, et al. Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated vasculitis: a multi-center retrospective cohort study. BMC Nephrol. 2019;20(1):58. Published 2019 Feb 18. https://doi.org/10.1186/s12882-019-1226-0.

Neumann I. Immunosuppressive and glucocorticoid therapy for the treatment of ANCA-asssociated vasculitis. Rheumatology (Oxford). 2020;59(Suppl 3):iii60-iii67. https://doi.org/10.1093/rheumatology/keaa035.

•• Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020;382(7):622–31. https://doi.org/10.1056/NEJMoa1803537. (This trial tested the efficacy of plasma exchange and two different glucocorticoid dosing regimens for remission indcution in AAV.)

Article  CAS  PubMed  PubMed Central  Google Scholar 

Junek ML, Merkel PA, Vilayur E, et al. The risk of relapse of ANCA-associated vasculitis in a randomized controlled trial of plasma exchange and glucocorticoids. Arthritis Rheumatol. Published online March 14, 2024. https://doi.org/10.1002/art.42843.

Furuta S, Nakagomi D, Kobayashi Y, et al. Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial. JAMA. 2021;325(21):2178–87. https://doi.org/10.1001/jama.2021.6615.

Article  CAS  PubMed  Google Scholar 

Xiao Y, Guyatt G, Zeng L, et al. Comparative efficacy and safety of alternative glucocorticoids regimens in patients with ANCA-associated vasculitis: a systematic review. BMJ Open. 2022;12(2):e050507. Published 2022 Feb 25. https://doi.org/10.1136/bmjopen-2021-050507.

Zeng L, Walsh M, Guyatt GH, et al. Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: a clinical practice guideline. BMJ. 2022;376:e064597. Published 2022 Feb 25. https://doi.org/10.1136/bmj-2021-064597.

Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221–32. https://doi.org/10.1056/NEJMoa0909905.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211–20. https://doi.org/10.1056/NEJMoa0909169.

Article  CAS  PubMed  Google Scholar 

Geetha D, Specks U, Stone JH, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol. 2015;26(4):976–85. https://doi.org/10.1681/ASN.2014010046.

Article  CAS  PubMed  Google Scholar 

Hiepe F, Radbruch A. Plasma cells as an innovative target in autoimmune disease with renal manifestations. Nat Rev Nephrol. 2016;12(4):232–40.